Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Unknown 2Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lung Neoplasms 2Head and Neck Neoplasms 2Xerostomia 1Thyroid Carcinoma, Anaplastic 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neutropenia 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × pegfilgrastim × Clear all
NCT00681044 2017-04-28

HD Melphalan and SCT in Patients With IGDD or LCDD

Boston Medical Center

Phase 2 Terminated
5 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡